# Yifeng Capital

> Yifeng Capital is a VC fund backing Biotechnology, Medical and Health Care. See 18 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 18
- Last investment: Mar 2026
- Lead investor: 33%
- Last updated: Aug 2026

Yifeng Capital is a VC fund focused on Biotechnology and Medical. Yifeng Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 39% |
| Medical | 6 | 33% |
| Health Care | 5 | 28% |
| Pharmaceutical | 5 | 28% |
| Biopharma | 4 | 22% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 33% |
| Series B | 5 | 28% |
| Seed | 4 | 22% |
| Angel | 1 | 6% |
| Series D | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 16 | 89% |
| Japan | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Huamei Haolian | Huamei Haolian specializes in providing telemedicine and medical tourism services. |  | Series D | Mar 02, 2026 |  |
| Century Kangtai | Century Kangtai is a Class III medical device manufacturer that combines production, research and development, and sales. Century Kangtai is a collagen material developer and ophthalmic clinical trial company. Its primary business is the research and development, production, and marketing of ocular implant devices, as well as the provision ofafter-sales services to consumers. It has computer numerical control air suspension and uses laser navigation technology and laser interference. Products that use measurement technology include integrated posterior chamber intraocular lenses, ocular fixation rings, and collagen sponges. |  | Series B | Sep 20, 2023 |  |
| Lingyi Biology | Lingyi Bio is a rare disease animal model functional verification platform and gene therapy developer. | $14.5M | Series A | May 06, 2023 |  |
| Trinomab | Trinomab is a Healthcare company. | $104.7M | Venture - Series Unknown | Nov 29, 2022 |  |
| Direct Drive Technology | Direct Drive Technology provides direct drive solutions to replace the reduction gears in any machine. The company has a complete set of technologies for robot joints from sensors, drivers to motor bodies. Drive Tech uses a unique direct drive precise & powerful motion solution, thereby helping many other industries to boost different products. |  | Series A | Oct 14, 2022 |  |
| Xingsai Bio | Xingsai Bio is a developer of single-cell analysis instruments and supporting reagents and consumables. |  | Seed | Jun 27, 2022 |  |
| Beimei Pharmaceutical | Beimei Pharmaceutical is a biotech company focusing on the research and deveopment of children's prescription drugs. | $15.7M | Series B | Apr 02, 2022 |  |
| West Lake Omi | Westlake Omi combines proteomic big data with artificial intelligence, mass spectrometry-based biological sample digitization technology. |  | Seed | Jan 13, 2022 |  |
| Westlake Omics | Westlake Omics focuses on applying mass spectrometry-based proteomics and other Omics technologies to address pressing clinical needs. It is committed to making breakthroughs in precision medicine and drug R&D with an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomicanalysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data.It was founded in 2020 and is based in Hangzhou, Zhejiang, China. |  | Seed | Jan 13, 2022 |  |
| BioInno | Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets. |  | Series A | Dec 21, 2021 |  |

10 of 18 investments shown.

## Co-investors
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 4 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 3 deals together
- AstraZeneca CICC Medical Industry Fund — VC Fund, 2 deals together
- Tigermed — VC Fund, 2 deals together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 2 deals together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-investment) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Yifeng Capital invest in?

Yifeng Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yifeng Capital last invest?

The most recent investment recorded for Yifeng Capital closed in Mar 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co